Skip to content

Bluejay Diagnostics, Inc.: 10-Q filed 2024-11-07

What Bluejay Diagnostics, Inc. reported in its quarterly report filed 2024-11-07 (fiscal Q3 2024): 38 published measures, 106 facts as tagged in accession 0001213900-24-095388.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-07
Fiscal period
fiscal Q3 2024
Accession
0001213900-24-095388 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Bluejay Diagnostics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-308,353,410USD
At 2023-12-314,868,531USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-301,188,976USD
At 2023-12-311,973,683USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-307,164,434USD
At 2024-06-308,641,075USD
At 2024-03-313,367,226USD
At 2023-12-312,894,848USD
At 2023-09-305,213,155USD
At 2023-06-306,376,339USD
At 2023-03-319,163,395USD
At 2022-12-3111,541,273USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-305,755,741USD
At 2023-12-312,208,516USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,481,959USD92
2024-01-01 to 2024-09-30-6,285,804USD274
2024-04-01 to 2024-06-30-2,475,380USD91
2024-01-01 to 2024-03-31-2,328,465USD91
2023-07-01 to 2023-09-30-2,297,998USD92
2023-01-01 to 2023-09-30-7,651,146USD273
2023-04-01 to 2023-06-30-2,813,305USD91
2023-01-01 to 2023-03-31-2,539,843USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-6,081,083USD274
2023-01-01 to 2023-09-30-5,536,393USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-09-30305,658USD274
2023-01-01 to 2023-09-30616,272USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-309,933,966USD274
2023-01-01 to 2023-09-301,114,612USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-305,658USD274
2023-01-01 to 2023-09-30-616,272USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-33,236,794USD
At 2023-12-31-26,950,990USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-309,555,855shares92
2024-01-01 to 2024-09-303,444,646shares274
2023-07-01 to 2023-09-30137,871shares92
2023-01-01 to 2023-09-30131,054shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-309,555,855shares92
2024-01-01 to 2024-09-303,444,646shares274
2023-07-01 to 2023-09-30137,871shares92
2023-01-01 to 2023-09-30131,054shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.16USD/shares92
2024-01-01 to 2024-09-30-1.82USD/shares274
2023-07-01 to 2023-09-30-16.67USD/shares92
2023-01-01 to 2023-09-30-58.38USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.16USD/shares92
2024-01-01 to 2024-09-30-1.82USD/shares274
2023-07-01 to 2023-09-30-16.67USD/shares92
2023-01-01 to 2023-09-30-58.38USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-301,534,631USD
At 2023-12-311,285,741USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-09-3022,676USD274
2023-01-01 to 2023-09-30204,810USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,361,607USD92
2024-01-01 to 2024-09-30-5,684,972USD274
2023-07-01 to 2023-09-30-2,341,233USD92
2023-01-01 to 2023-09-30-7,924,493USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-306,567,686USD
At 2023-12-313,220,860USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-07-01 to 2024-09-30185,893USD92
2024-01-01 to 2024-09-30807,797USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-301,049,247USD
At 2023-12-311,771,375USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-30316,650USD
At 2023-12-31491,474USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,361,607USD92
2024-01-01 to 2024-09-305,684,972USD274
2023-07-01 to 2023-09-302,341,233USD92
2023-01-01 to 2023-09-307,924,493USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-30551,655USD92
2024-01-01 to 2024-09-302,917,674USD274
2023-07-01 to 2023-09-301,397,318USD92
2023-01-01 to 2023-09-304,428,123USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3017,827,280shares
At 2023-12-31154,893shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-305,755,741USD
At 2023-12-312,208,516USD
At 2023-09-305,076,937USD
At 2022-12-3110,114,990USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-09-30227,495USD
At 2023-12-31333,267USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-09-30241,652USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-09-302,834,888USD
At 2023-12-312,529,457USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-301,300,257USD
At 2023-12-311,243,716USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-09-3023,598USD
At 2023-12-3128,663USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-09-309,530USD
At 2023-12-3112,321USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-09-30811,945USD
At 2023-12-31747,263USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30809,199USD92
2024-01-01 to 2024-09-302,759,817USD274
2023-07-01 to 2023-09-30963,534USD92
2023-01-01 to 2023-09-303,213,614USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-01-01 to 2024-09-3055,843USD274
2023-01-01 to 2023-09-30626,366USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-120,352USD92
2024-01-01 to 2024-09-30-600,832USD274
2023-07-01 to 2023-09-3043,235USD92
2023-01-01 to 2023-09-30273,347USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-09-301,590,840USD273

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-01-01 to 2024-09-30132,642USD274
2023-01-01 to 2023-09-30130,692USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-387,478USD274
2023-01-01 to 2023-09-3018,609USD273

Inspect the source

Entity
Bluejay Diagnostics, Inc. / CIK 0001704287
Captured
2026-09-21T17:24:11.325Z
SEC response SHA-256
7b576f6ad0703490f74bfda11e23abf7bf7547bf44a012503e93b7ff7bb8b6a6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001704287.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))